Hypertension Drugs Newly Prescribed or Continued in the U.S., 1994-2007TriMark PublicationsDecember 15, 2008 SKU: TRI2047489 |
|
Croatia in 2030: The Future Demographic
5/9/2012 | published by: Euromonitor International
Croatia is experiencing depopulation which will continue over the next 20 years. The population is ageing steadily and life expectancy is rising. Fertility rate and birth rate are low, leading to natural depopulation. Emigration from
|
more...
|
$900.00
|
|
Israel in 2030: The Future Demographic
5/9/2012 | published by: Euromonitor International
In 2030, the population of Israel will reach 10.1 million, an increase of 32.9% from 2010. Females outlive males and the gap will increase over time. The Israeli immigrant population is highly educated, and includes
|
more...
|
$900.00
|
|
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
4/19/2012 | published by: Global Markets Direct
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Ukraine in 2030: The Future Demographic
4/18/2012 | published by: Euromonitor International
In 2030, the population of Ukraine will reach 42.6 million, a decrease of 7.0% from 2010. Total population in Ukraine has been falling since the mid 1990s. Much of the immigration to Ukraine is actually
|
more...
|
$900.00
|
|
Singapore in 2030: The Future Demographic
4/5/2012 | published by: Euromonitor International
In 2030, the population of Singapore will reach 6.0 million, an increase of 17.5% from 2010. Singapore is an attractive destination for immigrants and net migration has been positive since the mid nineties, except during
|
more...
|
$900.00
|
|
South African Segment Report: Mass Market - LSM 5
3/23/2012 | published by: Analytix Business Intelligence
This 83 page Powerpoint report examines the LSM 5 segment of South Africa and provides a comprehensive profile of the LSM 5 segment (mass market). In 2011, 17% of all South African adults lived in
|
more...
|
$950.00
|
|
South African Segment Report: Emerging Market (LSM 7)
3/29/2012 | published by: Analytix Business Intelligence
This 85 page PowerPoint report examines the LSM 7 segment of South Africa and provides a comprehensive profile of the LSM 7 segment (emerging market). In 2011, 11.0% of all South African adults lived in
|
more...
|
$950.00
|
|
South African Segment Report: Mass Market - LSM 6
3/30/2012 | published by: Analytix Business Intelligence
This 91 page PowerPoint report examines the LSM 6 segment of South Africa and provides a comprehensive profile of the LSM 6 segment (mass market). In 2011, 21% of all South African adults lived in
|
more...
|
$950.00
|
|
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
3/23/2012 | published by: GBI Research
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research “Anti-Hypertensives Market to 2017 -
|
more...
|
$3,500.00
|
|
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
3/31/2012 | published by: GlobalData
Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 Summary GlobalData, Industry analysis specialist, has released its new report, “Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to
|
more...
|
$6,995.00
|
